Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDK4/6 Inhibitors + Endocrine Therapy in Neoadjuvant HR+/HER2- Breast Cancer
NCT06810492Not yet recruiting
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of ribociclib, abemaciclib, palbociclib and dalpiciclib in breast cancer. Primary endpoint: Objective Response Rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
ribociclibabemaciclibpalbociclibdalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06810492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810492.